Эффективность и безопасность вакцины Превенар у детей и взрослых групп риска

06.06.2010

Литература

  1. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) // MMWR Recomm Rep. 2000. V. 49. (RR-9). P. 1 - 35.
  2. Miller E., Waight P., Efstratiou A. et al. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996 - 1998 // Acta Paediatr. 2000. Suppl. 89 (435). P. 11 - 16.
  3. Eskola J., Takala A.K., Kela E. et al. Epidemiology of invasive pneumococcal infections in children in Finland // JAMA. 1992. V. 268. № 23.P. 3323 - 3327.
  4. Barnett E.D., Pelton S.I., Cabral H.J. et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children // Clin Infect Dis. 1999. V. 29. № 1. P. 191, 192.
  5. Sorensen R.U., Leiva L.E., Giangrosso P.A. et al. Response to a heptava-lent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine // Pediatr Infect Dis J. 1998. V. 17. № 8. P. 685 - 691.
  6. Rose M.A., Schubert R., Strand N. et al. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-va-lent polysaccharide pneumococcal vaccine // Clin Diagn Lab Imminol. 2005. V. 12. № 10. P. 1216 - 1222.
  7. Breukels M.A., Rijkers G.T., Voorhorst-Ogink M.M. et al. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta // J Infect Dis. 1999.V. 179. № 5. P. 1152 - 1156.
  8. Pelton S.I., Abzug M.J., Borkowsk W. et al. Functional antibody responses to PCV-PPV regiment in HIV infected children on HAART categorized by entry and nadir CD4 percentage (PACT1024) [abstract PO6.21] // Paper presented at: 5th International Symposium on Pneumococci and Pneu-mococcal Diseases (ISPPD). Alice Springs, Central Australia. - 2006.April 2 - 6.
  9. King J.C., Vink P.E., Farley J.J. et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiancy virus infection // Pediatrics. 1997. V. 99. № 4. P 575 - 580.
  10. Spoulou V.I., Tsoumas D.L., Papaevangelou V.G. et al. Immunogenicity and immunological memory induced by a 7-valent pneumo^^al CRM197 conjugate vaccine in symptomatic HIV-1 infected children // Vaccine. 2005. V. 23. № 46, 47. P. 5289 - 5293.
  11. Madhi S.A., Kuwanda L., Cutland C. et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children // Pediatr Infect Dis J. 2005. V. 24. № 5. P. 410 - 416.
  12. King J.C., Jr, Vink P.E., Farley J.J. et al. Comparison of the safety and immu-nogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children // Pediatr Infect Dis J. 1996. V. 15. № 3.P. 192 - 196.
  13. O'Brien K.L., Swift A.J., Winkelstein J.A. et al. Safety and immunogenecity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease // Pneumococcal Conjugate Vaccine Study Group Pediatrics. 2000. V. 106. № 5. P 965 - 972.
  14. Vernacchio L., Neufeld E.J., MacDonald K. et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneu-mococcal vaccine in children and young adults with sickle cell disease //J Pediatr. 1998. V. 133. № 2. P. 275 - 278.
  15. Stray-Pedersen A., Aaberge I.S., Fruh A. et al. Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia // Clin Exp Immunol. 2005.V. 140. № 3. P. 507 - 516.
  16. Schubert R., Reichenbach J., Rose M. et al. Immunogenecity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangi-ectasia // Pediatr Infect Dis J. 2004. V. 23. № 3. P. 269, 270.
  17. Molrine D.C., George S., Tarbell N. et al. Antibody responses to polysac-charide and polysaccharide-conjugate vaccines after treatment of Hodg-kin's disease // Ann Intern Med. 1995. V. 123. № 11. P. 828 - 834.
  18. Chan C.Y., Molrine D.C., George S. et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease // J Infect Dis. 1996. V. 173. № 1.P. 256 - 258.
  19. Molrine D.C., Antin J.H., Guinan E.C. et al. Donor immunization with pneu-mococcal cpnjugate vaccine and early protective antibody responsesfollowing allogenic hematopoietic cell transplantation // Blood. 2003. V. 101. № 3. P. 831 - 836.
  20. Antin J.H., Guinan E.C., Avigan D. et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation // Biol Blood Marrow Transplant. 2005. V. 11. № 3. P. 213 - 222.
  21. Lin P.L., Michaels M.G., Green M. et al. Safety and immunogenecity of the American Academy of Pediatrics-recommended sequential pneu-mococcal conjugate and polysaccharide vaccine schedule in pediat-ric solid organ transplant recipients // Pediatrics. 2005. V. 116. № 1.P. 160 - 167.
  22. Kumar D., Rotstein C., Miyata G. et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients // J Infect Dis. 2003. V. 187. № 10. P 1639 - 1645.
  23. Ruckinger S., Van der Linden M., Von Kries R. Effect of heptavalent pneu-mococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants // BMC Infectious Diseases. 2010. V. 10. № 12.P. 1 - 4.
  24. Barton M., Wasfy S., Dipchand A.l. et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenecity // Pediatr Infect Dis J. 2009. V. 28.№ 8. P. 688 - 692.
  25. Rose M.A., Gruendler M., Schubert R. et al. Safety and immunogenecity of sequential pneumococcal immunization in preschool asthmatics // Vaccine. 2009. V. 27. № 38. P. 5259 - 5264.
  26. Rendi-Wagner P., Paulke-Korinek M., Kundi M. et al. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases // Vaccine. 2009. V. 27. № 30.P. 3963 - 3968.
  27. Cordonnier C., Labopin M., Chesnel V. et al. Ramdomized study of early versus late immunization with pneumococcal conjugate vaccine after al-logeneic stem cell transplantation // Clin Infect Dis. 2009. V. 48. № 10.P. 1392 - 1401.
  28. Madhi S.A., Klugman K.P., Kuwanda L. et al. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfectad children 5 years after vaccination // The Journal of Infectious Deseases. 2009. V. 199. P 1168 - 1176.
  29. Orthopoulos G.V., Theodoridou M.C., Ladis V.A. et al. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with beta-thalassemia // Vaccine. 2009. V. 27. № 3. P 350 - 354.
  30. Vieira S., Baldacci E.R., Carneiro-Sampaio M. et al. Evaluation of antibody response to heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease // Pediatr Nephrol. 2009. V. 24. № 1. P. 83 - 89.
  31. Stanford E., Print F., Falconer M. et al. Immune response to pneumococcal conjugate vaccination in asplenic individuals // Human Vaccines. 2009.V. 5. № 2. P. 85 - 91.
  32. Micoluc B., Kayhty H., Bernatowska E. et al. Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children // Eur J Clin Microbiol Infect Dis. 2008. V. 27. № 10. P. 923 - 928.
  33. Adamkiewicz T.V., Silk B.J., Howgate J. et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life // Pediatrics. 2008. V. 121. № 3. P. 562 - 569.
  34. Miguel-Martinez I., Ramos-Macias A., Barreiro S.B. Efficacy of heptavalent pneumococcal conjugate vaccine in children with cochlear implant // Acta Otorrinolaringol Esp. 2008. V. 59. № 1. P. 2 - 5.
  35. Sinisalo M., Vilpo J., Itala M. et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia // Vaccine. 2008. V. 10. № 11. P. 1407.
  36. Reinert P., Benkerrou M., de Montalembert M. et al. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease // Pediatr Infect Dis J. 2007. V. 26. № 12. P. 1105 - 1109.
  37. Balmer P., Borrow R., Arkwright P.D. The 23-valent pneumococcal poly-saccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptava-lent pneumococcal conjugate vaccine // Vaccine. 2007. V. 25. № 34.P. 6321 - 6325.
  38. Smets F., Bourgois A., Vermylen C. et al. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine // Vaccine. 2007.V. 25. № 29. P. 5278 - 5282.
  39. Rose M., Hey C., Kujumdshiev S. et al. Immunogenicity of pneumococcal vaccination of patients with cochlear implants // The Journal of InfectiousDiseases. 2004. V. 190. № 1. P. 551 - 557.